2972 related articles for article (PubMed ID: 7617079)
1. Synergistic antitumor activity of tumor necrosis factor-alpha and lovastatin against MmB16 melanoma in mice.
Feleszko W; Lasek W; Gołab J; Jakóbisiak M
Neoplasma; 1995; 42(2):69-74. PubMed ID: 7617079
[TBL] [Abstract][Full Text] [Related]
2. Synergistic antiproliferative activity of tumor necrosis factor alpha (TNF-alpha) and lovastatin.
Sora MK; Kruszewski AA; Stokłosa T; Czyzyk J; Lasek W; Malejczyk J; Jakóbisiak M
Arch Immunol Ther Exp (Warsz); 1994; 42(4):269-74. PubMed ID: 7487365
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effect of interleukin 7 in combination with local hyperthermia in mice bearing B16a melanoma cells.
Wu B; Shen RN; Wang WX; Broxmeyer HE; Lu L
Stem Cells; 1993 Sep; 11(5):412-21. PubMed ID: 8241952
[TBL] [Abstract][Full Text] [Related]
4. Augmented antitumor effects of combination therapy with interleukin-12, cisplatin, and tumor necrosis factor-alpha in a murine melanoma model.
Zagozdzon R; Stokłosa T; Gołab J; Giermasz A; Dabrowska A; Lasek W; Jakóbisiak M
Anticancer Res; 1997; 17(6D):4493-8. PubMed ID: 9494557
[TBL] [Abstract][Full Text] [Related]
5. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice.
Feleszko W; Mlynarczuk I; Balkowiec-Iskra EZ; Czajka A; Switaj T; Stoklosa T; Giermasz A; Jakóbisiak M
Clin Cancer Res; 2000 May; 6(5):2044-52. PubMed ID: 10815931
[TBL] [Abstract][Full Text] [Related]
6. Lack of antitumour activity of human recombinant tumour necrosis factor-alpha, alone or in combination with melphalan in a nude mouse human melanoma xenograft system.
Furrer M; Altermatt HJ; Ris HB; Althaus U; Rüegg C; Liénard D; Lejeune FJ
Melanoma Res; 1997 Aug; 7 Suppl 2():S43-9. PubMed ID: 9578416
[TBL] [Abstract][Full Text] [Related]
7. Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice.
McIntosh JK; Mulé JJ; Krosnick JA; Rosenberg SA
Cancer Res; 1989 Mar; 49(6):1408-14. PubMed ID: 2784349
[TBL] [Abstract][Full Text] [Related]
8. Induction of tolerance allows separation of lethal and antitumor activities of tumor necrosis factor in mice.
Takahashi N; Brouckaert P; Fiers W
Cancer Res; 1991 May; 51(9):2366-72. PubMed ID: 1826631
[TBL] [Abstract][Full Text] [Related]
9. Lovastatin potentiates antitumor activity of doxorubicin in murine melanoma via an apoptosis-dependent mechanism.
Feleszko W; Młynarczuk I; Olszewska D; Jalili A; Grzela T; Lasek W; Hoser G; Korczak-Kowalska G; Jakóbisiak M
Int J Cancer; 2002 Jul; 100(1):111-8. PubMed ID: 12115596
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of the anti-tumor effect of actinomycin D by tumor necrosis factor alpha in mice: correlation between in vitro and in vivo results.
Lasek W; Giermasz A; Kuc K; Wańkowicz A; Feleszko W; Gołab J; Zagozdzon R; Stokłosa T; Jakóbisiak M
Int J Cancer; 1996 May; 66(3):374-9. PubMed ID: 8621260
[TBL] [Abstract][Full Text] [Related]
11. Granulocyte colony-stimulating factor demonstrates antitumor activity in melanoma model in mice.
Gołab J; Zagozdzon R; Stokłosa T; Kaca A; Dabrowska A; Giermasz A; Feleszko W; Jakóbisiak M
Neoplasma; 1998; 45(1):35-9. PubMed ID: 9605000
[TBL] [Abstract][Full Text] [Related]
12. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
[TBL] [Abstract][Full Text] [Related]
13. Antileukemic effects of recombinant human tumor necrosis factor alpha (rh-TNF alpha) with cyclophosphamide or methotrexate on leukemia L1210 and leukemia P388 in mice.
Warzocha K; Robak T
Acta Haematol Pol; 1992; 23(1):55-62. PubMed ID: 1615753
[TBL] [Abstract][Full Text] [Related]
14. Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha.
Crippa L; Gasparri A; Sacchi A; Ferrero E; Curnis F; Corti A
Cancer Res; 2008 Feb; 68(4):1154-61. PubMed ID: 18281491
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumor activity of recombinant tumor necrosis factor on mouse fibrosarcoma in vivo and in vitro.
Tomazic VJ; Farha M; Loftus A; Elias EG
J Immunol; 1988 Jun; 140(11):4056-61. PubMed ID: 3372997
[TBL] [Abstract][Full Text] [Related]
16. Potentiated antitumor effects of butyrate and actinomycin D in melanoma model in mice.
Giermasz A; Makowski M; Nowis D; Jalili A; Maj M; Dabrowska A; Czajka A; Jakobisiak M; Golab J
Oncol Rep; 2002; 9(1):199-203. PubMed ID: 11748483
[TBL] [Abstract][Full Text] [Related]
17. In vivo effects of purified recombinant human macrophage colony-stimulating factor in combination with local hyperthermia on tumor progression in B16a melanoma bearing mice.
Lu L; Xiao M; Wu B; Wang WX; Yan WR; Broxmeyer HE; Shen RN
Int J Hematol; 1993 Oct; 58(3):139-52. PubMed ID: 8148492
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo.
Fan QL; Zou WY; Song LH; Wei W
Cancer Chemother Pharmacol; 2005 Feb; 55(2):189-96. PubMed ID: 15290100
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents.
Studeny M; Marini FC; Dembinski JL; Zompetta C; Cabreira-Hansen M; Bekele BN; Champlin RE; Andreeff M
J Natl Cancer Inst; 2004 Nov; 96(21):1593-603. PubMed ID: 15523088
[TBL] [Abstract][Full Text] [Related]
20. Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin.
Sacchi A; Gasparri A; Curnis F; Bellone M; Corti A
Cancer Res; 2004 Oct; 64(19):7150-5. PubMed ID: 15466213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
